Biotech Pipeline Accelerates: Inside Ginkgo Bioworks and Pulse Biosciences' Latest Moves

The biomedicine and health sector is currently undergoing its most significant overhaul in recent years, driven by pipeline advancements and strategic reorganizations. I'm told that as capital markets adjust their expectations for early-stage biotech ventures, several companies focused on cell programming and novel ablation technologies are aggressively accelerating their clinical and commercial steps. According to people familiar with the matter, internal consolidations are quietly taking shape across the industry.

Pulse Biosciences (PLSE.US)

I'm told that Pulse Biosciences is entering a critical validation phase for its proprietary nanosecond pulsed field ablation (nsPFA) technology. Earlier in April 2026, the company successfully enrolled its first patients in the pivotal clinical study for its nPulse cardiac catheter system. On the financial front, the company reported USD 400K in Q1 2026 revenue with over USD 68.3M in cash equivalents. According to insiders, the company is also planning to redeem its remaining common stock warrants later this year to optimize its capital structure.

Ginkgo Bioworks (DNA.US)

As a notable player in cell programming, Ginkgo Bioworks is pushing forward with a major business restructuring. While Q1 2026 revenue dropped 49% year-over-year to USD 19M, the company has officially completed the spin-off of its biosecurity business. I'm told management is shifting focus entirely to high-margin services—launching the ADME-One platform in late May to significantly lower the costs of early-stage drug discovery. This directly follows the March debut of Ginkgo Cloud Lab, opening its automated infrastructure to external researchers.

Shenzhen Hepalink Pharmaceutical Group (SHECY.US)

Amid intense global competition, Shenzhen Hepalink remains one of the largest heparin producers worldwide. Recent data shows a sharp recovery in its profitability, with its latest half-year net profit soaring over 400%. The company's enoxaparin sodium preparations have now surpassed 110M syringes globally. Analysts tracking the company point out that the steady growth of its macromolecular biologic CDMO services provides a solid buffer through broader market cycles.

Also

• Singular Genomics Systems (SERV.US): Although taken private by Deerfield Management in early 2025, I'm told its spatial pathology business continues to progress, recently appointing John Stark as the new CEO in April 2026 to drive the adoption of its G4X platform.
• Blaze Bioscience (BLZE.US): Development of tozuleristide for pediatric central nervous system tumors continues, with the industry keeping a close eye on upcoming clinical trial updates.
• Agile Therapeutics (AGRX.US): Its previous acquisition and delisting by Insud Pharma remains a frequently cited benchmark for strategic consolidation within the women's health space.

This article does not constitute investment advice.